Brief: Immunoscape Signs Deal With Cue Biopharma To Develop Solid Tumor Cancer Treatment
13/11/2025 18:37
Nov 13 (Reuters) - ImmunoScape: IMMUNOSCAPE: ENTERED IN-LICENSING DEAL WITH CUE BIOPHARMA FOR DEVELOPMENT OF NEW CLASS OF THERAPIES TO ATTACK SOLID TUMOR CANCERS Source text: ID:nBw8LPGPFa Further company coverage: AMGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cue Biopharma
See all newsU.S. STOCKS ON THE MOVE-Insmed, Marvell, Meta
US STOCKS ON THE MOVE-Meta, Marvell Technology, Insmed
U.S. STOCKS ON THE MOVE-Accenture, Arhaus, Alkermes
Cue Biopharma surges after positive results from mid-stage study for CUE-221
Brief: Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria